- To ensure the optimum clinical outcome for all Fusion Health® products
- To strengthen the traditional and scientific evidence to support product indications
- To facilitate an ongoing commitment to innovation in product development and proprietary research.
Paul Keogh (ND, DMH) is Executive and Technical Director of Global Therapeutics P/L trading as FUSION® health. Paul is a qualified Naturopath and Medical Herbalist with 26 years combined experience in clinical practice, and the research and development of a therapeutic range of integrated Chinese and Western herbal medicines.
Dr. Shu Wang (MB of TCM) has 40 years of clinical experience practicing Traditional Chinese Medicine (TCM) and acupuncture in both China and Sydney, Australia. Shu is the director of the Chinese Medicine and Acupuncture Society of Australia, chief editor of a number of respected TCM journals, and a senior lecturer in TCM at Tianjin Medical University, China.
Dr. Fangming Jin (PhD, MPharmSc, BSc (TCM)) is a TCM Pharmacologist holding a PhD in Pharmacy (Herbal Medicine). Fangming gained extensive experience in pre-clinical research and the analysis of herbal medicines at the Nanjing University of TCM, Shaanxi TCM University and the University of Tasmania. As Research Associate with Global Therapeutics, she offers unique insight and a wealth of knowledge on all aspects of scientific research.
Johan du Toit (B Economics) is engaged by Global Therapeutics as Strategic Advisor. His experience in natural healthcare includes Managing Director roles over a period of 12 years. With Global Therapeutics his role is dedicated to business strategy and advising on strengthening of the company’s intellectual property.
Claire Briggs (ND, BSc) is a qualified Naturopath with extensive experience in the complementary medicines industry. At Global Therapeutics Claire applies her talents and skills to managing complex technical projects involving product development, scientific research, technical writing and regulatory affairs.